Showing results (51-60 of 60) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Advanced Drug Delivery Reviews|February 4, 2024
Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findingsMichael Z Liao, Dan Lu, Tong Lu, et al.Pharmaceutical Research|December 1, 2020
Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin LymphomaDan Lu, Tong Lu, Rong Shi, et al.CPT: Pharmacometrics & Systems Pharmacology|April 16, 2024
Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX studyRong Deng, Leonid Gibiansky, Tong Lu, et al.CPT: Pharmacometrics & Systems Pharmacology|November 22, 2019
Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non-Hodgkin LymphomaDan Lu, Tong Lu, Leonid Gibiansky, et al.Clinical Pharmacology and Therapeutics|June 27, 2025
Tocilizumab Dosing for Management of T Cell-Engaging Bispecific Antibody-Related CRS in Patients With R/R B-Cell NHLCandice Jamois, David C Turner, Leonid Gibiansky, et al.Journal of Pharmacokinetics and Pharmacodynamics|September 18, 2017
Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugatesMatts Kågedal, Leonid Gibiansky, Jian Xu, et al.British Journal of Clinical Pharmacology|March 14, 2019
Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapyCandice Jamois, Ekaterina Gibiansky, Leonid Gibiansky, et al.Leukemia & Lymphoma|September 25, 2019
Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO studyRong Deng, Leonid Gibiansky, Tong Lu, et al.Clinical Pharmacology and Therapeutics|May 10, 2025
Dose Selection for DuoBody®-CD40x4-1BB (GEN1042/BNT312) Using a mPBPK/RO Model Leveraging Preclinical and Clinical DataGaurav Bajaj, Dmitry Shchelokov, Oleg Demin, et al.Clinical Pharmacokinetics|June 19, 2019
Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO StudyRong Deng, Leonid Gibiansky, Tong Lu, et al.Pageof 6